ES
MARKETS / NASDAQ / LNAI
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Lunai Bioworks Inc. LNAI

14 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
EPS · FY24
$-1.08
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-321.8%
Net margin · FY24
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2024 · full 14-year series below
Revenue Net income
2e-054e-056e-05-0.2201120142017202020232024
2e-054e-056e-05-0.22015201820212024

Per share
USD -1.08
Diluted EPS, FY2024
EPS
0.40.81.2-1.08201120142017202020232024
0.40.81.2-1.082015201820212024

The company pays no cash dividend.

Profitability
-321.8%
Return on equity, FY2024
ROE
0.250.50.751-321.8%201120142017202020232024
0.250.50.751-321.8%2015201820212024
Operating margin—
Net margin—
Return on assets-207.8%

Each USD of equity lost 322 cents this year.

Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.18B
Shares outstanding, FY2024
0.010.18201120142017202020232024
0.010.182015201820212024
Change, 5 years+76.1%
Change, 10 years—

The share count grew 76% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.2M
total assets, end of FY2024
Total assetsUSD 8.2M
EquityUSD -21.3M
CashUSD 92,700.00
Gross debtUSD 3.6M
Net debtUSD 3.5M
Current ratio0.04×

Net debt stands at -16% of equity.

History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
·
·
·
·
·
·
·
·
·
0.0
0.0
0.0
·
0.0
Operating income $B
−0.2
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.2
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
0.0
0.0
·
0.0
−0.0
·
·
−0.0
−0.0
−0.0
−0.0
·
·
0.0
Net income $B
−0.2
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.08
−0.91
−0.71
−2.16
−0.57
−0.25
−0.48
−0.29
−0.17
−0.18
−0.32
−0.40
·
0.00
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−321.8
−99.1
−66.6
−91.7
−15.7
−6.7
−10.9
−7.9
−478.7
−122.0
−263.7
·
·
·
Shares out B
0.18
0.16
0.06
0.05
0.05
0.05
0.05
0.04
0.01
0.01
0.01
0.01
0.01
0.01

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed